Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2015466

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2015466

Toxoplasmosis Testing Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global toxoplasmosis testing market is gaining notable momentum as healthcare systems worldwide intensify their focus on early diagnosis and infectious disease management. Toxoplasmosis, an infection caused by the parasite Toxoplasma gondii, remains a significant public health concern, particularly among pregnant women and individuals with weakened immune systems. The need for timely and accurate detection is driving the adoption of advanced diagnostic solutions. The market is projected to reach USD 2.4 billion in 2026 and is anticipated to grow to USD 3.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.50% during the forecast period.

Market Insights

The toxoplasmosis testing market is evolving with a wide array of diagnostic technologies, including serological assays, molecular diagnostics, and imaging techniques. Serological testing continues to dominate due to its affordability and accessibility, while molecular methods such as polymerase chain reaction (PCR) are increasingly preferred for their precision and reliability.

The growing burden of zoonotic diseases and the expansion of routine screening programs, particularly in prenatal care, are contributing to market growth. Additionally, advancements in laboratory automation and digital diagnostic platforms are enhancing testing efficiency and reducing turnaround times, making diagnostics more effective and scalable.

Market Drivers

A key factor driving market growth is the rising global incidence of toxoplasmosis infections. The infection can spread through contaminated food, water, and exposure to infected animals, making it a widespread risk across both developed and developing regions.

Increasing awareness regarding the importance of early detection is another major growth driver. Early diagnosis is essential in preventing severe complications, especially congenital infections that can have long-term health implications.

Technological progress in diagnostic tools is further accelerating market expansion. The development of highly sensitive and specific testing methods, along with automation in laboratories, is improving diagnostic accuracy and accessibility.

In addition, the growing population of elderly individuals and immunocompromised patients is increasing the demand for reliable testing solutions. These vulnerable groups require regular monitoring, further supporting the growth of the market.

Business Opportunity

The toxoplasmosis testing market offers substantial opportunities for industry participants. Emerging economies in Asia Pacific and Latin America are expected to be key growth areas due to improving healthcare infrastructure and rising investments in healthcare services.

There is a growing demand for point-of-care testing solutions that deliver rapid and accurate results. These technologies are particularly valuable in remote and resource-limited settings, where access to centralized laboratories may be limited.

Moreover, the integration of advanced technologies such as artificial intelligence and data analytics into diagnostic platforms is opening new avenues for innovation. These tools can enhance diagnostic accuracy, streamline workflows, and support clinical decision-making.

Strategic collaborations, product launches, and acquisitions are also creating opportunities for market players to strengthen their presence and expand their product offerings. Continuous investment in research and development is expected to drive innovation and competitiveness in the market.

Region Analysis

North America continues to hold a leading position in the toxoplasmosis testing market, supported by advanced healthcare systems, high awareness levels, and strong adoption of innovative diagnostic technologies. The presence of major industry players further reinforces the region's dominance.

Europe represents a significant share of the market, driven by increasing government initiatives and a strong emphasis on maternal and neonatal health. The region's well-established healthcare infrastructure supports widespread adoption of diagnostic testing.

Asia Pacific is projected to witness the fastest growth over the forecast period. Rapid urbanization, rising healthcare expenditure, and increasing awareness about infectious diseases are key factors contributing to market expansion in the region.

Latin America and the Middle East & Africa are also experiencing gradual growth, supported by ongoing improvements in healthcare access and increasing focus on disease prevention and early diagnosis.

Key Players

The global toxoplasmosis testing market is characterized by the presence of several prominent players focused on innovation and strategic expansion. Key companies include:

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Affymetrix Inc.
  • Beckman Coulter Inc.
  • Biotest
  • Cepheid Inc.
  • GenBio
  • Danaher Corporation
  • Thermo Fisher Scientific
  • Biomerica Inc.
  • Biomerix

These organizations are actively engaged in developing advanced diagnostic solutions and expanding their global footprint through partnerships and product innovations.

Segmentation

By Test Type:

  • Serological Test
  • Dye Test
  • Indirect Hemagglutination Assay
  • Direct agglutination Assay
  • ELISA
  • PCR
  • Ultrasound
  • MRI
  • Biopsy

By Sample:

  • Blood Sample
  • Amniotic Fluid
  • Cerebrospinal Fluid

By End User:

  • Hospitals
  • Clinics
  • Diagnostic Laboratories

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Toxoplasmosis Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Toxoplasmosis Testing Market Outlook, 2020-2033

  • 3.1. Global Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Serological Test
    • 3.1.2. Dye Test
    • 3.1.3. Indirect Hemagglutination Assay
    • 3.1.4. Direct agglutination Assay
    • 3.1.5. ELISA
    • 3.1.6. PCR
    • 3.1.7. Ultrasound
    • 3.1.8. MRI
    • 3.1.9. Biopsy
  • 3.2. Global Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 3.2.1. Blood Sample
    • 3.2.2. ABniotic Fluid
    • 3.2.3. Cerebrospinal Fluid
  • 3.3. Global Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospitals
    • 3.3.2. Clinics
    • 3.3.3. Diagnostic Laboratories
  • 3.4. Global Toxoplasmosis Testing Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Toxoplasmosis Testing Market Outlook, 2020-2033

  • 4.1. North America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Serological Test
    • 4.1.2. Dye Test
    • 4.1.3. Indirect Hemagglutination Assay
    • 4.1.4. Direct agglutination Assay
    • 4.1.5. ELISA
    • 4.1.6. PCR
    • 4.1.7. Ultrasound
    • 4.1.8. MRI
    • 4.1.9. Biopsy
  • 4.2. North America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 4.2.1. Blood Sample
    • 4.2.2. ABniotic Fluid
    • 4.2.3. Cerebrospinal Fluid
  • 4.3. North America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Diagnostic Laboratories
  • 4.4. North America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.2. U.S. Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 4.4.3. U.S. Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.5. Canada Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 4.4.6. Canada Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Toxoplasmosis Testing Market Outlook, 2020-2033

  • 5.1. Europe Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Serological Test
    • 5.1.2. Dye Test
    • 5.1.3. Indirect Hemagglutination Assay
    • 5.1.4. Direct agglutination Assay
    • 5.1.5. ELISA
    • 5.1.6. PCR
    • 5.1.7. Ultrasound
    • 5.1.8. MRI
    • 5.1.9. Biopsy
  • 5.2. Europe Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 5.2.1. Blood Sample
    • 5.2.2. ABniotic Fluid
    • 5.2.3. Cerebrospinal Fluid
  • 5.3. Europe Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospitals
    • 5.3.2. Clinics
    • 5.3.3. Diagnostic Laboratories
  • 5.4. Europe Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.2. Germany Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.3. Germany Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.5. Italy Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.6. Italy Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.7. France Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.8. France Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.9. France Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.11. U.K. Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.12. U.K. Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.14. Spain Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.15. Spain Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.17. Russia Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.18. Russia Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.20. Rest of Europe Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 5.4.21. Rest of Europe Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Toxoplasmosis Testing Market Outlook, 2020-2033

  • 6.1. Asia Pacific Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Serological Test
    • 6.1.2. Dye Test
    • 6.1.3. Indirect Hemagglutination Assay
    • 6.1.4. Direct agglutination Assay
    • 6.1.5. ELISA
    • 6.1.6. PCR
    • 6.1.7. Ultrasound
    • 6.1.8. MRI
    • 6.1.9. Biopsy
  • 6.2. Asia Pacific Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 6.2.1. Blood Sample
    • 6.2.2. ABniotic Fluid
    • 6.2.3. Cerebrospinal Fluid
  • 6.3. Asia Pacific Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospitals
    • 6.3.2. Clinics
    • 6.3.3. Diagnostic Laboratories
  • 6.4. Asia Pacific Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.2. China Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.3. China Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.5. Japan Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.6. Japan Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.8. South Korea Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.9. South Korea Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.10. India Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.11. India Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.12. India Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.14. Southeast Asia Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.15. Southeast Asia Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.17. Rest of SAO Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 6.4.18. Rest of SAO Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Toxoplasmosis Testing Market Outlook, 2020-2033

  • 7.1. Latin America Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Serological Test
    • 7.1.2. Dye Test
    • 7.1.3. Indirect Hemagglutination Assay
    • 7.1.4. Direct agglutination Assay
    • 7.1.5. ELISA
    • 7.1.6. PCR
    • 7.1.7. Ultrasound
    • 7.1.8. MRI
    • 7.1.9. Biopsy
  • 7.2. Latin America Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 7.2.1. Blood Sample
    • 7.2.2. ABniotic Fluid
    • 7.2.3. Cerebrospinal Fluid
  • 7.3. Latin America Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Diagnostic Laboratories
  • 7.4. Latin America Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.2. Brazil Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.3. Brazil Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.5. Mexico Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.6. Mexico Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.8. Argentina Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.9. Argentina Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.11. Rest of LATAM Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 7.4.12. Rest of LATAM Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Toxoplasmosis Testing Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Serological Test
    • 8.1.2. Dye Test
    • 8.1.3. Indirect Hemagglutination Assay
    • 8.1.4. Direct agglutination Assay
    • 8.1.5. ELISA
    • 8.1.6. PCR
    • 8.1.7. Ultrasound
    • 8.1.8. MRI
    • 8.1.9. Biopsy
  • 8.2. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Sample, Value (US$ Bn), 2020-2033
    • 8.2.1. Blood Sample
    • 8.2.2. ABniotic Fluid
    • 8.2.3. Cerebrospinal Fluid
  • 8.3. Middle East & Africa Toxoplasmosis Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Diagnostic Laboratories
  • 8.4. Middle East & Africa Toxoplasmosis Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.2. GCC Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.3. GCC Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.5. South Africa Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.6. South Africa Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.8. Egypt Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.9. Egypt Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.11. Nigeria Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.12. Nigeria Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East Toxoplasmosis Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.14. Rest of Middle East Toxoplasmosis Testing Market Outlook, by Sample, 2020-2033
    • 8.4.15. Rest of Middle East Toxoplasmosis Testing Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Abbott Laboratories
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Bio-Rad Laboratories Inc.
    • 9.4.3. Affymetrix Inc.
    • 9.4.4. Beckman Coulter Inc.
    • 9.4.5. Biotest
    • 9.4.6. Cepheid Inc.
    • 9.4.7. GenBio
    • 9.4.8. Danaher Corporation
    • 9.4.9. Thermo Fisher Scientific

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!